If you would like to learn more about the IAEA’s work, sign up for our weekly updates containing our most important news, multimedia and more.
Application of FDG-PET and Molecular Gene Profiling for Risk Stratification of Diffuse Large B-Cell Non-Hodgkin’s Lymphoma in Different Ethnic Populations
Closed for proposals
Project Type
Project Code
E15020CRP
1379Approved Date
Status
Start Date
Expected End Date
Completed Date
31 December 2012Description
Diffuse Large B-Cell non-Hodgkin’s Lymphoma (DLBCL) is an aggressive form of non-Hodgkin’s Lymphoma (NHL). During the past 30 years the treatment of DLBCL has evolved to a point where the disease is curable in many patients. The introduction of Positron Emission Tomography (PET) has made a critical contribution to the accurate definition of clinical stage at presentation and the accurate assessment of disease clearance at the end of treatment. More recently early interim PET has been shown to be a good indicator of potential for cure. Gene expression profiling (GEP) of DLBCL has been demonstrated to identify disease subsets with both biological and clinical significance and to provide an independent predictor of response to treatment.
Objectives
To establish the application of novel nuclear based and related in vitro molecular and biotechnological methods for effective investigation and management of infectious, neoplastic, metabolic, genetic and degenerative diseases in Member States.
Specific objectives
To develop prognostic algorithms to improve the treatment and outcome of patients with aggressive non-Hodgkin’s Lymphoma in developing countries.